Immunovaccine to Present at 6th Annual Biotech Showcase Conference
HALIFAX, NOVA SCOTIA -- (Marketwired) -- 01/09/14 -- Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company") (TSX VENTURE:IMV), a clinical stage vaccine and immunotherapy company, today announced that the Company will present at the 6thAnnual Biotech Showcase Conference. The conference will take place January 13-15, 2014 at the Parc 55 Wyndham San Francisco Union Square Hotel.
Details of Immunovaccine's presentation are as follows:
|Event:||Biotech Showcase™ 2014 Conference|
|Date:||Monday, January 13, 2014|
|Location:||Room Mission II, Parc 55 Wyndham San Francisco Union Square Hotel|
Marc Mansour, Ph.D., Chief Operating Officer of Immunovaccine, will present a corporate update including the latest developments for the Company's two clinical-stage cancer vaccines, as well as its proprietary DepoVax™ vaccine adjuvanting delivery platform.
Immunovaccine expects three trials to be initiated in 2014 with its cancer immunotherapies, the largest of which is a randomized Phase II trial of DPX-Survivac in ovarian cancer being sponsored and conducted by Canada's NCIC Clinical Trials Group (NCIC CTG). The trial is expected to begin enrolling the first of its 250 patients in 2014. Additionally, researchers at the University of Rome have announced plans to initiate a Phase II trial of DPX-Survivac in glioblastoma (brain cancer) patients in the first half of 2014. A third trial, using DPX-0907 to treat breast and ovarian cancer, is planned for initiation at Busto Arsizio Hospital in Milan.
About Ovarian Cancer
Ovarian cancer accounts for more deaths than any other gynecologic cancer. Symptoms do not occur until it is in the later stages of the disease, reducing the chance for successful treatment and remission. It kills more than 100,000 women annually around the world. Improved surgical techniques have helped to reduce the rate of recurrence according to some studies, but the average life expectancy of newly diagnosed ovarian cancer patients is less than four years.
Glioblastoma, the most common form of brain cancer, is a fast-growing tumor type that develops from astrocytes, a type of glial cell present in the brain. The National Cancer Institute estimates that more than 23,000 Americans will be diagnosed with brain and other nervous system tumors in 2013. Glioblastoma accounts for approximately 15 percent of all brain tumors. The current standard of care for glioblastoma patients calls for patients to receive maximum surgical resection combined with radiation and concomitant and adjuvant temozolomide therapy. Newly diagnosed glioblastoma patients have a median overall survival of less than 24 months.
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.
Connect at www.imvaccine.com.
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, including information regarding the use of proceeds of the financing, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Dr. Marc Mansour
Chief Operating Officer
Vida Strategic Partners (media)
Source: Immunovaccine Inc.
Released January 9, 2014